Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/28/2025 | $118.00 | Buy → Hold | HSBC Securities |
4/4/2025 | Buy → Hold | Argus | |
2/11/2025 | $160.00 | Mkt Perform | Bernstein |
1/2/2025 | $315.00 → $138.00 | Overweight → Neutral | Piper Sandler |
12/20/2024 | $230.00 → $164.00 | Outperform → Market Perform | BMO Capital Markets |
12/16/2024 | $175.00 | Buy → Hold | Stifel |
12/10/2024 | $178.00 | Neutral | BofA Securities |
12/9/2024 | $250.00 → $180.00 | Buy → Hold | Jefferies |
HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00
Argus downgraded Biogen from Buy to Hold
Bernstein initiated coverage of Biogen with a rating of Mkt Perform and set a new price target of $160.00
Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will eval
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
8-K - BIOGEN INC. (0000875045) (Filer)
DEFA14A - BIOGEN INC. (0000875045) (Filer)
144 - BIOGEN INC. (0000875045) (Subject)